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Increasing rates of antibiotic resistance among Gram-negative
pathogens such as Pseudomonas aeruginosa means alternative
approaches to antibiotic development are urgently required.
Pyocins, produced by P. aeruginosa for intraspecies competition,
are highly potent protein antibiotics known to actively translocate
across the outer membrane of P. aeruginosa. Understanding and
exploiting the mechanisms by which pyocins target, penetrate
and kill P. aeruginosa is a promising approach to antibiotic
development. In this work we show the therapeutic potential of
a newly identified tRNase pyocin, pyocin SD2, by demonstrating
its activity in vivo in a murine model of P. aeruginosa lung
infection. In addition, we propose a mechanism of cell targeting
and translocation for pyocin SD2 across the P. aeruginosa outer
membrane. Pyocin SD2 is concentrated at the cell surface,
via binding to the common polysaccharide antigen (CPA) of
P. aeruginosa lipopolysaccharide (LPS), from where it can
efficiently locate its outer membrane receptor FpvAI. This
strategy of utilizing both the CPA and a protein receptor for cell
targeting is common among pyocins as we show that pyocins
S2, S5 and SD3 also bind to the CPA. Additional data indicate a
key role for an unstructured N-terminal region of pyocin SD2 in
the subsequent translocation of the pyocin into the cell. These
results greatly improve our understanding of how pyocins target
and translocate across the outer membrane of P. aeruginosa. This
knowledge could be useful for the development of novel anti-
pseudomonal therapeutics and will also support the development
of pyocin SD2 as a therapeutic in its own right.
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INTRODUCTION
Pseudomonas aeruginosa is a Gram-negative opportunistic
pathogen notable for being the leading cause of mortality in
patients with cystic fibrosis [1]. Additionally, P. aeruginosa is
the principle organism associated with burn wound infections
[2], the most prevalent Gram-negative bacteria associated with
nosocomial and ventilator associated pneumonia [3] and the
second most common cause of catheter-associated urinary tract
infections [4]. Together with many bacterial pathogens, there
is an increasing prevalence of multi-drug resistance (MDR) in
P. aeruginosa, which has resulted in limited treatment options for
patients [5]. In 2013 there were an estimated 51000 health-care
associated P. aeruginosa infections in the U.S.A., more than 13%
of which were classed as MDR [6]. Furthermore, the prevalence
of pan-drug resistant P. aeruginosa isolates (non-susceptibility
to all antibiotics in all antimicrobial classes) is also increasing,
resulting in a return to a pre-antibiotic era for many patients with
P. aeruginosa infections [7–12]. Therefore, there is an urgent
requirement to develop novel antibiotics to treat this drug resistant
pathogen.
P. aeruginosa utilizes intrinsic, acquired and adaptive
mechanisms for antibiotic resistance. These include but are not
limited to: inherently low levels of outer membrane permeability;
expression of multi-drug efflux pumps and antibiotic degrading
enzymes (e.g. β-lactamases); accumulation of mutations in
antibiotic targets; acquisition of genetic elements encoding
resistance genes; alteration of growth state (e.g. biofilm formation)
and phenotypic variation (e.g. appearance of small colony and
mucoid variants in the population). The outer membrane of P.
aeruginosa is estimated to be 10–100-fold less permeable to
small hydrophilic molecules, including antibiotics, than that of
Escherichia coli [13]. As well as this intrinsic outer membrane
impermeability, P. aeruginosa employs several mechanisms of
altering the outer membrane composition to reduce both the
lipid-mediated uptake of hydrophobic antibiotics and porin-
mediated diffusion of hydrophilic antibiotics across the outer
membrane. These include the loss of the carbapenem-specific
porin OprD, reduction in cell envelope Mg2 + and Ca2 + ,
alterations in lipopolysaccharide (LPS) O-antigen composition
and alterations of the lipid A and core oligosaccharide moieties
of LPS [5,14,15]. As the outer membrane of P. aeruginosa
poses a formidable barrier to antibiotic treatment, identifying and
exploiting new ways to target and penetrate the outer membrane is
essential for the successful development of new anti-pseudomonal
antibiotics.
Abbreviations: CFU, colony-forming units; CPA, common polysaccharide antigen; ITC, isothermal titration calorimetry; LPS, lipopolysaccharide; MDR,
multi-drug resistance.
1 Correspondence may be addressed to either of these authors (email Laura.mccaughey@uts.edu.au or daniel.walker@glasgow.ac.uk).
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Pyocins are protein antibiotics produced by P. aeruginosa
for intraspecies competition [16]. They can take the form of a
DNase, tRNase, pore former or they can inhibit peptidoglycan
synthesis, and they parasitize P. aeruginosa-specific nutrient
uptake pathways to achieve active transport across the outer
membrane. These extremely potent anti-pseudomonal proteins
represent excellent tools for antibiotic development; not only
can they provide great insight into new ways to target and
penetrate the outer membrane they are also promising therapeutics
in their own right. To date the outer membrane receptors for
three pyocins have been identified. These are FpvAI, FpvAII and
FptA, all of which are involved in the uptake of iron-siderophore
complexes [17–20]. Pyocin L1 has also been shown to bind
to the common polysaccharide antigen (CPA) of P. aeruginosa
LPS, a homopolymer of the rare deoxyhexose D-rhamnose, as
a way of targeting cells [21]. Outside the identification of outer
membrane receptors utilized by pyocins, little is known about
the mechanisms involved in pyocin translocation and much of our
understanding, including the assignment of domain functionalities
(e.g. receptor binding, translocation and cytotoxic domains [16])
is inferred from research on colicins (protein antibiotics produced
by and active against E. coli [22]).
In the case of the E-type colicins, two outer membrane
proteins are required for binding and translocation across the
outer membrane: a high-affinity receptor and a translocator. Once
bound to their high-affinity receptors, via their receptor-binding
domains, colicins search the outer membrane landscape for their
translocators via lateral diffusion. This is facilitated by the 45◦
orientation of the elongated receptor-binding domain of the colicin
to the membrane plane, known as the ‘fishing pole’ mechanism
[23]. Translocation then requires the N-terminal intrinsically
unstructured translocation domain of the colicin to thread through
the central pore of the translocator protein where it can interact
with components of the import machinery (the TonB system or the
Tol system) via specific Tol or TonB boxes [23–25]. The next steps
in the translocation of E-type colicins across the outer membrane
remain largely unknown. However, the end goal of cell death is
known to occur via a DNase, tRNAse, rRNase or pore forming
functionality. For the smaller, globular colicin M, which uses only
one copy of FhuA for binding and translocation, the intrinsically
unstructured translocation domain is much shorter (37 residues)
but is similarly positioned at the N-terminus and includes a TonB
box (residues 2–8) [26,27]. Colicin N is unique among colicins
in that it binds to both LPS on the surface of E. coli and to the
general porin OmpF in order to cross the outer membrane [28]. It
is unlikely that one model can describe the mechanism of binding
and translocation for both pyocins and colicins as these form a
diverse group of proteins, differing in size, structure and activity
[16,21,22,29,30].
In this work we have identified and purified three pyocins,
SD1, SD2 and SD3, with N-terminal domains homologous with
pyocins S1, S2 and S3 respectively, and C-terminal cytotoxic
domains that are homologous with the tRNase domain of colicin
D. Through in vivo studies we show that pyocin SD2 can afford
protection against a lethal P. aeruginosa lung infection in a murine
model, demonstrating its potential for therapeutic development.
In vitro characterization of pyocin SD2 indicates that only one
copy of the outer membrane receptor FpvAI is used by pyocin
SD2 and the TonB box on FpvAI is essential for pyocin SD2
activity. Furthermore, the first 17 amino acids of pyocin SD2 are
essential for cytotoxic activity, but are not involved in receptor
binding. In addition, we show that pyocin SD2 binds to the CPA
of P. aeruginosa LPS and that CPA-binding is required for high
efficiency killing of P. aeruginosa. Together these results suggest
that pyocin SD2 utilizes both the CPA and FpvAI to target P.
aeruginosa and that a predicted unstructured N-terminal region
of pyocin SD2 is critical for subsequent translocation.
MATERIALS AND METHODS
Strains and plasmids
The strains and plasmids used in this study are described in
Supplementary Table S1. Strains of E. coli and P. aeruginosa
were grown in LB broth at 37 ◦C.
Cloning of pyocins
Pyocin S2 was cloned as previously described [31]. Pyocin SD2-
imSD2 was amplified from the genomic DNA of the producing
strain P. aeruginosa MSH10 by PCR using primers designed to
introduce an NdeI site at the start of the pyoSD2 gene (TGT CAA
CAT ATG GCT GTC AAT GAT TAC GAA CC) and an XhoI site
at the end of the pyoSD2-im gene (TGT CAA CTC GAG TAT
GTA TTT ATA TTC TTT CAA TAG ATC ACT C). For pyocin
S217 primers were designed to introduce an NdeI site 17 amino
acids into the pyoS2 gene (TGT CAA CAT ATG GGT GGT GGG
CGT GAC ATA AT). For pyocin S2318, primers were designed
to introduce an NdeI site before residue 318 of the pyoS2 gene
(C GCT CGT CAA GCG GCG CAT ATG GCT GCC AAT ACT
TAT G). The N-terminal portions were removed by digestion
with NdeI. For pyocin S2(1–209), primers were designed to
introduce an XhoI site after residue 209 of the pyoS2 gene by
site-directed mutagenesis (G GAG GCG GAC TAC AAG CTC
GAG AAG GCA AAT GTC GAG). The PCR product was digested
with XhoI to remove intervening DNA. The PCR products were
ligated into the corresponding sites of the E. coli expression
vector pET21a to give pETPyoSD2 which encodes pyocin SD2-
imSD2, pETPyoS217 which encodes pyocin S217-imS2,
pETPyo209 which encodes pyocin S2(209) and pETPyoS2318
which encodes pyocin S2318-imS2, all with C-terminal His6
tags. The gene encoding pyocin S5 was similarly amplified from
the genomic DNA of strain PAO1 using primers designed to
introduce an NdeI site at the start of the gene (GAG ACA TAT
GTC CAA TGA CAA CGA AGT AC) and an XhoI site after
the stop codon (TTT GAC GTC TCG AGT TAA ATG GAT ATT
ACA AGA TTG TTT GC). The digested PCR product was ligated
into pET15b to give pETPyoS5, which encodes pyocin S5 with
an N-terminal His6-tag. The genes encoding pyocin AP41 and
its immunity protein (ImAP41) were amplified from the genomic
DNA of P. aeruginosa C763 by PCR using primers designed to
introduce an NdeI site at the start of the pyocin encoding gene
(ACA GAT CAT ATG AGC GAC GTT TTT GAC CTT GG) and
an XhoI in place of the stop codon of the ImAP41 encoding gene
(ACA GAT CTC GAG GCC AGC CTT GAA GCC AGG G). The
PCR product was digested with NdeI and XhoI and ligated into the
corresponding sites of the E. coli expression vector pET21a to give
pETPyoAP41, which was used for the production of the pyocin
AP41–ImAP41 complex in which ImAP41 carries a C-terminal
His6-tag. Pyocins SD1, SD3 and SD2216 were synthesized by
GenScript, US, and ligated into pET21a using NdeI and XhoI
restriction sites to produce complexes in which the immunity
proteins carry C-terminal His6-tags.
Purification of pyocins
All pyocins and pyocin variants used in this study were
overexpressed from E. coli BL21(DE3)pLysS carrying the
corresponding plasmids. For each pyocin, 5 litres of LB broth
c© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution Licence 4.0 (CC BY).
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containing 100 μg · ml− 1 of ampicillin was inoculated (1:100)
from an overnight culture and cells were grown at 37 ◦C in
a shaking incubator to an OD600 = 0.6. Protein production
was induced by the addition of 1.0 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) and cells were grown at 37 ◦C
for a further 3.5 h before harvesting by centrifugation. Cells
were resuspended in 20 mM Tris/HCl, 500 mM NaCl, 20 mM
imidazole, pH 7.5, lysed and the cell debris separated by
centrifugation. The cell-free lysate was applied to a 5 ml
HisTrap column (GE Healthcare) equilibrated in 20 mM Tris/HCl,
500 mM NaCl, 20 mM imidazole, pH 7.5, and the pyocins
eluted over a 20–500 mM imidazole gradient. Pyocin containing
fractions were pooled, dialysed overnight into 50 mM Tris/HCl,
200 mM NaCl, pH 7.5 and remaining contaminants removed by
gel filtration chromatography on a Superdex S200 16/60 column
or Superdex S75 26/60 column (GE Healthcare) equilibrated in the
same buffer. The proteins were concentrated using a centrifugal
concentrator (Amicon Ultra 15, MerckMillipore) with a molecular
weight cut off of 5 kDa and stored at − 80 ◦C. Prior to use protein
concentrations were determined using a NanoDrop (NanoDrop
ND1000, Thermo Scientific).
Overlay spot plate method
One hundred and fifty microlitres of test strain culture at
OD600 = 0.6 was added to 6 ml of 0.8% agar and poured over an
LB agar plate. Five or ten microlitres of purified pyocin at various
concentrations was spotted on to overlay plates and incubated for
24 h at 37 ◦C. Clear zones indicate killing.
Bactericidal activity assay in liquid culture
For pyocin SD2 receptor saturation experiments, P. aeruginosa
PAO1 was grown in LB broth with shaking at 37 ◦C to OD600
= 0.2. The culture was then divided into four separate flasks.
Pyocin SD2 was added to a final concentration of 6.3 μg · ml− 1,
63 μg · ml− 1 and 630 μg · ml− 1 to three separate flasks. Growth
was continued with shaking at 37 ◦C and the OD600 of the untreated
and pyocin-treated cultures were monitored at 20 min intervals.
The highest concentration of pyocin SD2 used (630 μg · ml− 1)
resulted in 13.7 × 106 pyocin SD2 molecules per cell.
For pyocin SD2-CPA killing efficiency experiments, cells at a
middle-log phase were adjusted to an OD600 = 0.4. One millilitre
aliquots of the cells were mixed with pyocin SD2 at a final
concentration of 3 μM. The mixtures were incubated at 37 ◦C
with shaking at 180 rpm for 30 min, 60 min, 90 min and 180 min.
The OD600 was recorded at each time point and the cell aliquots
from each time point were used to calculate colony-forming units
(CFU).
Secondary structure prediction and sequence alignments
To predict secondary structure features PSIPRED-software was
used [32]. The prediction was applied to the whole sequence.
Pyocin protein sequence alignments were created using CLC
Main Workbench 7. The alignments were manually checked for
conserved regions and domain boundaries. Precise delineation of
the FpvAI binding domain will be reported elsewhere.
SAXS
SAXS was carried out on the X33 beamline at the Deutsches
Elektronen Synchrotron (DESY). Data were collected on samples
of pyocin in the range of 0.5–5 mg · ml− 1. Buffer was scattered
before and after each sample and an average of the buffer
scattering was subtracted from the sample scattering. The data
obtained for each sample were analysed using PRIMUS [33],
merging scattering data at low angles with high angle data. The
pair distance distribution function, p(r), was obtained by indirect
Fourier transform of the scattering intensity using GNOM [34].
A Guinier plot [ln(I) vs S2] was used to calculate the radius
of gyration, Rg, of the pyocin complex. An ab initio model of
the protein complex in solution was built using DAMMIF [35].
Twenty independent reconstructions produced similar shapes and
these were averaged using DAMAVER [36].
LPS purification and isolation of LPS-derived polysaccharide
LPS was purified from 1 litre cultures of P. aeruginosa strains as
described previously, with modifications including the omission
of the final trifluoroacetic acid hydrolysis and chromatography
steps [37]. Cells were grown for 20 h at 37 ◦C, pelleted by
centrifugation at 6000 g for 20 min and resuspended in 50 mM
Tris/HCl, pH 7.5 containing lysozyme (2 mg · ml− 1) and DNase I
(0.5 mg · ml− 1). Cells were lysed by sonication and the cell lysate
was incubated at 20 ◦C for 30 min before EDTA was added to a
final concentration of 2 mM. An equal volume of aqueous phenol
was added and the solution was heated at 70 ◦C for 20 min, with
vigorous mixing. The solution was then cooled on ice for 30 min,
centrifuged at 7000 g for 20 min and the aqueous phase extracted.
Proteinase K was added to a final concentration of 0.05 mg · ml− 1
and dialysed for 12 h against 2 × 5 litres dH2O. LPS was pelleted
by ultracentrifugation at 100000 g for 1 h, resuspended in dH2O
and heated to 60 ◦C for 30 min to remove residual proteinase
K activity. LPS-derived carbohydrates were isolated by heating
LPS in 2% acetic acid for 1.5 h at 96 ◦C. Lipid A was removed
by centrifugation at 13500 g for 3 min followed by extraction
with an equal volume of chloroform. The aqueous phase was then
lyophilized.
Isothermal titration calorimetry
Isothermal titration calorimetry (ITC) experiments were
performed on a VP-ITC microcalorimeter or using a MicroCal
iTC200 microcalorimeter at 25 ◦C (MicroCal). Pyocins or pyocin
variants were used as the titrant at various concentrations (Table 2,
Supplementary Table S2) with LPS-derived carbohydrates
dissolved at 1 mg · ml− 1 or 3 mg · ml− 1 (Table 2, Supplementary
Table S2) in the chamber. Prior to analysis protein concentrations
were determined using a NanoDrop (NanoDrop ND1000, Thermo
Scientific). Reactions were performed in 0.2 M sodium phosphate
buffer, pH 7.5. For curve fitting the molar concentration of
LPS-derived CPA containing carbohydrate chains was estimated
at 20 μM, based on an estimated average molecular weight
of 10 kDa for CPA containing polysaccharides and estimating
the percentage of total LPS represented by CPA containing
carbohydrates as 20% of the total by weight [38]. The N-value
equals the stoichiometry when the concentrations used for fitting
are correct and 100% active. As the concentration of CPA in the
cleaved LPS sugars is an estimate the stoichiometry implied by
the fit is likely to be unreliable. However, the use of this estimated
value has no impact on the reported parameters of H, S and Kd.
All samples were degassed extensively prior to the experiments.
The heats of dilution for protein into buffer for each titration were
obtained and subtracted from the raw data. Data were fitted to
a single-binding site model with Microcal LLC Origin software.
Errors reported in the text are the S.E.M. from the average of
c© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution Licence 4.0 (CC BY).
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two experiments. Errors reported in the figure legends are the
standard error of the fit for the experiment shown in the figure.
All ITC binding parameters and errors are reported in Table 2. For
pyocin SD2216 to PAO1 LPS sugars a flat curve was obtained
due to the Kd being in the mid micromolar range. As these curves
lacked an inflection point the N value was fixed to a constant value
during the fit. This value was 0.1, which was the approximate N-
value for pyocins SD2, S2, S5 and SD3 binding to PAO1 LPS
sugars.
Far-UV CD
Proteins in 0.2 M sodium phosphate buffer, pH 7.5 at 25 ◦C were
diluted to a concentration of 15–150 μg · ml− 1 and far-UV CD
spectra were recorded on a J-815 spectropolarimeter (Jasco) in
a 0.1 cm quartz cuvette using scanning speed of 20 nm · min− 1,
a step size of 0.5 nm and digital integration time of 1 s. Spectra
are an average of three scans and are buffer baseline corrected.
The final spectra were represented by molar ellipticity, ε
(mdeg · M− 1 · cm− 1).
Ethics statement
All animal experiments were performed in accordance with the
UK Animals (Scientific procedures) Act, authorized under a
UK Home Office License, and approved by the animal project
review committee of the University of Glasgow. Animal studies
were not randomized and blinding was not possible in this
study. The project license number assigned by the animal
project review committee of the University of Glasgow was
60/4361.
Murine model of acute P. aeruginosa lung infection
Six-week-old, female, murine pathogen free C57/BL6 mice
(Charles Rivers Laboratories) weighing 15–21 g were inoculated
intranasally with 25 μl of bacterial culture containing
approximately 107 CFU of P. aeruginosa PAO1 after induction
of anaesthesia with isofluorane. Pyocins SD2 and S2 dissolved
in PBS (25 μl at 3 mg · ml− 1) (n = 6) were delivered via the
intranasal route, after induction of anaesthesia with isofluorane,
1 h post-infection and were administered only once. To determine
if mice could survive infection after pyocin SD2 treatment, mice
were monitored closely, culled by carbon dioxide asphyxiation
when required as determined by a scoring system or culled at
the pre-determined 24 h time point. The scoring system assessed
illness (mild/moderate/severe) based on whether the mice were
starey, hunched, lethargic or moribund. The maximum overall
score that resulted in a mouse being culled was seven (two for
starey, hunched and lethargic and one for moribund). However,
if a mouse scored one for moribund but did not score six in
the other categories, it was still culled. For CFU determination,
lungs were removed aseptically and kept on ice in 750 μl of PBS
until homogenized. Serial 10-fold dilutions of the homogenized
lung were plated on Pseudomonas selective agar (20 g peptone,
1.5 g K2HPO4, 1.5 g MgSO4 · 7H2O, 10 ml glycerol, 15 g agar,
0.025 g Irgasan per litre) and incubated at 37 ◦C for 24 h and
then room temperature for 24 h before the colonies were counted.
To determine pyocin SD2 resistance of recovered colonies the
overlay spot plate method was used.
RESULTS AND DISCUSSION
Discovery and characterization of pyocins SD1, SD2 and SD3
The genomes of 15 P. aeruginosa clinical and environmental
isolates [39], including PAO1 [40], PA14, PA7 and LESB58, were
analysed for putative pyocin producing genes by searching for
sequences homologous with those of known bacteriocin genes.
We identified three putative pyocin and immunity protein gene
pairs. These encoded tRNase-type pyocins and their associated
immunity proteins [39] (Table 1). The cytotoxic domains of
these putative pyocins share between 51% and 55% amino
acid identity with the cytotoxic domain of colicin D (Figure 1).
Colicin D is a tRNase-type colicin [41] and four of the six
residues critical for cytotoxic activity in colicin D (K608, H611,
S677 and W679) are conserved in the putative pyocins. The
immunity protein genes share between 30% and 32% amino
acid identity with the colicin D immunity protein (Figure 1).
Sequences N-terminals to the cytotoxic domains of these putative
pyocins share significant homology with pyocins S1, S2 or S3.
Consequently, we designated these putative pyocins as pyocin
SD1, pyocin SD2 and pyocin SD3 respectively. To determine
the killing spectrum of pyocins SD1, SD2 and SD3 we cloned
the pyocin and immunity protein open reading frames for each
pyocin-immunity protein pair into the pET21a vector, resulting in
a His6-tag on the C-terminal end of the immunity protein. Pyocins
SD1-imSD1, SD2-imSD2 and SD3-imSD3 were expressed in
BL21(DE3)pLysS cells and purified by nickel affinity and size
exclusion chromatography. Pyocins SD1, SD2 and SD3 contain
591, 662 and 740 amino acids respectively, in the pyocin
protein and range in size from 63 kDa to 79 kDa. The immunity
proteins of all three contain 90 amino acids and are 10 kDa
in size (Table 1, Figure 1b). Pyocin SD1 killed 5/63 clinical
and environmental P. aeruginosa isolates tested, pyocin SD2
killed 6/63 isolates including PAO1, and pyocin SD3 showed
activity against 15/63 isolates. Killing was observed down to a
concentration of approximately 12 nM for all three pyocins. A
recent review identified genes encoding pyocins SD2 and SD3
using bioinformatics approaches and designated them as pyocins
S11 and S12 [42]. However, as pyocins S7–S10 have not been
experimentally validated, to maintain consistency in the literature,
we propose the alternative designations SD2 and SD3.
Domain organization
The domain organization of colicin-like pyocins such as S2
and SD2 is thought to differ from that of the colicins, which
have an N-terminal translocation domain, followed by a central
receptor-binding domain and a C-terminal cytotoxic domain, in
that the order of the translocation and receptor-binding domains
is reversed [16,22]. In addition, some colicin-like pyocins appear
to possess an additional domain of unknown function [16,22].
Therefore, for pyocins S2/SD2 the domain order from the N-
terminus is currently thought to be: receptor-binding domain,
unknown domain (not present in all pyocins), translocation
domain and cytotoxic domain (Figure 2a). Reversal of the order
of the receptor binding and translocation domains in pyocins
and colicins has implications in terms of pyocin translocation.
A centrally positioned translocation domain for pyocins does not
logically allow for an extended unstructured region to pass across
the outer membrane to the periplasm, as has been demonstrated for
colicins [23]. For this reason the domain architecture of pyocins
S2/SD2 was reassessed using secondary structure predictions and
sequence alignments of multiple pyocins. The first 50 amino
acids of pyocins S2/SD2 are predicted to largely lack regular
c© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution Licence 4.0 (CC BY).
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Table 1 Genome locations and sizes of pyocins SD1, SD2 and SD3
*Pyocin protein also present in 2 other p. aeruginosa strains on NCBI. Immunity protein present in 40 other P. aeruginosa strains on NCBI. †Pyocin protein also present in 102 other p. aeruginosa
strains on NCBI. Immunity protein present in 40 other P. aeruginosa strains on NCBI. ‡Pyocin protein also present in 2 other P. aeruginosa strains on NCBI. Immunity protein present in 17 other P.
aeruginosa strains on NCBI. 100 % coverage and > 90 % identity used for NCBI search.
Strain identified in Pyocin and immunity protein gene position Pyocin (amino acids) Immunity protein (amino acids) Pyocin + immunity protein (kDa)
Pyocin SD1* PA62 4170921 – 4172988(Not annotated) 591 90 63.4 + 10.1
Pyocin SD2† MSH10 4109138 – 4111400 662 90 71.5 + 10.1
(MSH10-3855 and MSH10-3856)
Pyocin SD3‡ PA7 3134080 – 3136575 740 90 78.5 + 10.3
(PA7-3036 and PA7-3037)
Figure 1 Discovery and purification of pyocins SD1, SD2 and SD3
(a) Comparison of the amino acid % identity for pyocins SD1, SD2 and SD3, with pyocins S1, S2, S3 and colicin D. The cytotoxic domains of pyocins SD1, SD2 and SD3 are homologous with
colicin D and the N-terminal domains are homologous with the respective pyocins. Pyocins SD1 and SD2 are nearly identical in their cytotoxic domains and immunity proteins. (b) SDS/PAGE gel
(4–12 %) of purified pyocins SD1 (63 kDa), SD2 (72 kDa) and SD3 (79 kDa) and their immunity proteins (10 kDa) post purification. (c) Pyocin S2(1–209) (1 mg · ml− 1) is not active against CF18.
(d) Inhibition of pyocin S2 killing (1 μg · ml− 1) by pyocin S2(1–209) (1 mg · ml− 1).
secondary structure and are rich in proline and glycine (Figure 2b).
Amino acids 50–318 of pyocins S2/SD2 are predicted to be
helical with a coiled-coil structure and do not appear to be two
separate domains as previously annotated (Figure 2b). The central
domain of pyocins was previously designated the ‘translocation
domain’ due to homology with the globular domain at the
N-terminus of many colicins [16]. However, it has yet to be
experimentally demonstrated that this conserved colicin/pyocin
domain (CCPD) has a direct role in colicin/pyocin translocation.
In fact, the role of this domain in the mode of action of these
proteins remains a mystery [23,25]. Sequence alignments of
pyocins S2/SD2 indicate that the cytotoxic domain of pyocin
SD2 encompasses the C-terminal residues 558–662. Based on
these structural and sequence alignment predictions the domain
architecture of pyocins S2/SD2 would be better described from
the N-terminus as follows: unstructured domain, helical domain,
conserved colicin/pyocin domain (CCPD) and cytotoxic domain
(Figure 2c).
Pyocin SD2 is highly elongated
To gain insight into the structural basis of pyocin translocation,
we obtained small angle X-ray scattering (SAXS) data for pyocin
SD2 in complex with its immunity protein, ImSD2. Data were
obtained for a range of pyocin SD2 concentrations. An ab initio
model of the pyocin SD2–imSD2 complex was generated using
DAMMIF and was a good fit to the experimental scattering data
(χ = 1.158) (Figures 3a and 3b). Ab initio modelling of the pyocin
SD2 envelope produced a dumbbell shape (Figure 3a), which
correlates with the presence of two maxima on the pair-distance
distribution plot for the pyocin SD2–imSD2 complex (Figure 3c).
The maximum particle dimension obtained from this graph
[Dmax = 215 Å (1 Å=0.1 nm)] shows the pyocin SD2–imSD2
complex to be an elongated molecule (Figure 3c). Guinier analysis
of the experimental scattering data (Figure 3d) shows that pyocin
SD2–imSD2 has a radius of gyration of 54.4 Å and is monomeric
in solution. These data show that similar to the E-type colicins,
pyocin SD2 is highly elongated with a large globular region at
one end, and a smaller globular region at the other end.
Pyocins S2/SD2 require a single copy of FvpAI for receptor binding
and translocation
The very high level of sequence identity between the non-
cytotoxic domains of pyocin S2 and pyocin SD2 suggests that
both proteins utilize the same cell-surface receptor. For pyocin S2
this has previously been shown to be the ferripyoverdine receptor
FpvAI [17]. To confirm FpvAI is also the receptor for pyocin
SD2, its activity was assessed against PAO1fpvA, a mutant of
the pyocin SD2-sensitive strain PAO1 with the fpvA gene deleted
[43]. Pyocin SD2 was not active against PAO1fpvA (Figures 4a
and 4b) and activity was restored after complementation with the
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Figure 2 Sequence alignment and secondary structure predictions for
pyocin SD2
(a) Previously proposed domain architecture of pyocin S2. (b) Predicted secondary structure
features of pyocin SD2 using PSIPRED-software [32]. The first 50 residues of pyocin SD2
have little regular secondary structure and are rich in proline and glycine residues. (c) Newly
proposed domain architecture of pyocin SD2.
fpvAI gene (Figure 4c). Consistent with this, pyocin SD2 killing
of P. aeruginosa PAO1 could be inhibited by the addition of
pyocin S2 in competition overlay spot plate assays (PAO1 is a
pyocin S2 producing strain and so is not killed by pyocin S2 due
to production of the cognate immunity protein ImS2) (Figures 4d
and 4e). These data show that pyocin SD2 uses FpvAI as a cellular
receptor.
In the case of the highly elongated colicin Ia, two copies of its
receptor Cir are required for colicin activity, with one copy acting
as a high-affinity receptor and the other as a translocation pore
[44]. Killing of E. coli is inhibited at high colicin Ia concentrations
as the high-affinity receptor-binding domain of colicin Ia binds all
copies of Cir. This leaves no unbound Cir molecules to interact
with the intrinsically unstructured translocation domains of the
bound colicins [44]. To determine if pyocin SD2, which has a
highly elongated structure similar to colicin Ia, requires two copies
of FpvAI on the cell surface for receptor binding and translocation,
the growth of P. aeruginosa PAO1 in the presence of 1×, 10× and
100× the MIC of pyocin SD2 was monitored (Figure 4g). All three
concentrations of pyocin SD2 were able to inhibit the growth of
P. aeruginosa PAO1, with no reduction in killing observed with
increasing concentration. At the highest concentration of pyocin
used there were 13.7 × 106 pyocin SD2 molecules present per
cell. Overlay spot plate assays were also used to test for FpvAI
saturation by pyocin SD2. The lack of a central zone of bacterial
growth or ‘halo’ within the clear zone of pyocin SD2 killing on the
spot plates shows that there is no receptor saturation at high pyocin
SD2 concentrations (300 μM). A lack of receptor saturation in the
growth assay and the spot plate assay indicates that pyocin SD2
requires only one copy of FpvAI for cell entry.
Figure 3 Small angle X-ray scattering model of pyocin SD2
(a) Ab initio model of pyocin SD2 computed with DAMMIF and averaged with DAMAVER. (b)
Overlay of the experimentally determined pyocin SD2 SAXS curve (black points) with the fit of
the ab initio model (purple line), produces a good fit (χ = 1.158). (c) Pair-distance distribution
plots from experimental scattering data for pyocin SD2 suggest that this protein is an elongated
multi-domain protein in solution. Dmax = 215 A˚. (d) Guinier plot of scattering data indicates
that pyocin SD2 is monomeric in solution. Radius of gyration is 54.4 A˚.
These data suggest either pyocins S2/SD2 function in a manner
similar to colicin M, which uses one copy of its TonB-dependent
receptor as both the primary receptor and the translocation pore,
or translocation occurs via a second distinct outer membrane
translocator protein as for the nuclease E colicins. In the case of
the E-type colicins, the primary TonB-dependent receptor, BtuB,
does not require an intact TonB box since translocation occurs via
the co-receptor or translocator, OmpF. However, for colicin M the
TonB-dependent receptor FhuA must carry an intact TonB box
for colicin M activity [26,45]. To determine if pyocin SD2 uptake
requires the FpvAI receptor to carry an intact TonB box, we tested
its ability to kill a PAO1 strain (PAO1fpvAattP::fpvATBM) that
produces a variant FpvAI carrying an altered (ATAAAAN) and
non-functional TonB box [43]. Pyocin SD2 was unable to kill
this strain showing that the TonB-FpvAI interaction is essential
for pyocin SD2 activity (Figure 4f). Based on the above data,
we conclude that pyocin S2/SD2 translocation is mechanistically
distinct from that of colicin Ia and the E-type colicins with
which they share a highly elongated structure. Instead, since
pyocin activity requires a single copy of FpvAI that carries an
intact TonB box, it is possible that a single copy of FpvAI acts
both as receptor and translocator, in a mechanism similar to
colicin M.
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Figure 4 Pyocin SD2 utilizes the outer membrane protein FpvAI
Ten microlitres of purified pyocin was spotted on to a growing lawn of cells. Clear zones indicate cell death. (a) Inhibition of growth of P. aeruginosa PAO1 by pyocin SD2 (1 mg · ml− 1). (b)
Pyocin SD2 (1 mg · ml− 1) is not active against PAO1fpvAI. (c) Pyocin SD2 killing (1 mg · ml− 1) is restored against PAO1fpvAI::fpvAI. (d) Pyocin S2 (2 mg · ml− 1) is not active against PAO1.
(e) Inhibition of pyocin SD2 killing (1 mg · ml− 1) by pyocin S2 (2 mg · ml− 1) against PAO1. (f) Pyocin SD2 (1 mg · ml− 1) is not active against PAO1fpvAI::fpvAITBM. (g) P. aeruginosa PAO1
was grown in LB broth with shaking at 37◦C to OD600 = 0.2. The culture was then divided into four separate flasks. Pyocin SD2 was added to a final concentration of 6.3 μg · ml− 1 (square),
63 μg · ml− 1 (triangle) and 630 μg · ml− 1 (star) to three separate flasks. Growth was continued with shaking at 37◦C and the OD600 of the untreated (circle) and pyocin-treated cultures were
monitored at 20 min intervals. Bars represent mean +− S.E.M. (n = 2). The highest concentration of pyocin SD2 used (630 μg · ml− 1) resulted in 13.7 × 106 pyocin SD2 molecules per cell. Killing
of PAO1 by pyocin SD2 was seen at all three pyocin concentrations.
The translocation domain of pyocins S2/SD2 is located at the
N-terminus
For colicin M both an intact TonB box in the receptor and
translocator FhuA and a TonB box located within the intrinsically
unstructured translocation domain of the colicin are essential
for activity. The first 50 amino acids of pyocins S2/SD2 are
proline and glycine rich and thus are likely to have little regular
secondary structure, reminiscent of the N-terminal intrinsically
unstructured translocation domain of some colicins (Figure 2b).
To further probe the mechanism of pyocin S2/SD2 translocation
we produced a truncated pyocin S2 variant (pyocin S217) that
lacked 17 amino acids from the N-terminus. This protein was
purified via a His6-tag on the immunity protein. Formation of the
pyocin–immunity protein complex demonstrates proper folding
of the cytotoxic domain of this truncated protein. Pyocin S217
was not active against the pyocin S2-sensitive clinical isolate P.
aeruginosa CF18 via overlay spot plate assays demonstrating
that the first 17 amino acids of pyocin S2 are essential for
activity (Figures 5a and 5b). Additionally, the receptor-binding
capabilities of this truncated protein remained intact, further
demonstrating folding of this truncated protein, as evidenced by
overlay spot plate competition assays (Figures 5c and 5d). This
shows that although the first 17 amino acids of pyocin S2 are
required for killing they are not involved in receptor binding. This
suggests a role for the mainly unstructured N-terminal region of
pyocins S2/SD2 in recruitment of translocation machinery. If the
mechanism of pyocin S2/SD2 is fully analogous to that proposed
for colicin M then it would be predicted that a ‘TonB box’ is
present within the first 17 amino acids of S2/SD2, although this
remains to be confirmed.
These and previous data [16,20] suggest that both the receptor-
binding and translocation functionality of pyocins S2/SD2 are
housed within the first 216 amino acids. This finding leaves the
function of amino acids 217–558 unknown. Therefore, we sought
to investigate their role in pyocin activity.
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Figure 5 The translocation domain is at the N-terminus of pyocins S2/SD2
Ten microlitres of purified pyocin was spotted on to a growing lawn of cells. Clear zones indicate
cell death. (a) Inhibition of growth of P. aeruginosa CF18 by pyocin S2 (0.1 μg · ml− 1). (b)
Pyocin S217 (750 μg · ml− 1) is not active against P. aeruginosa CF18. (c) Inhibition of
pyocin S2 killing (0.1 μg · ml− 1) by pyocin S217 (750 μg · ml− 1) against P. aeruginosa
CF18. (d) Inhibition of pyocin SD2 killing (100 μg · ml− 1) by pyocin S217 (750 μg · ml− 1)
against P. aeruginosa PAO1.
Pyocins S2/SD2 bind to the CPA of P. aeruginosa LPS
In recent work we showed that the CPA of P. aeruginosa LPS is
a cell-surface receptor for pyocin L1, a 32 kDa, globular, lectin-
like bacteriocin [21]. To determine if CPA-binding is involved
in S-type pyocin activity we assessed the activity of pyocin
SD2 against two P. aeruginosa PAO1 variants [46], which carry
transposon insertions in the genes wzt and wzm, both in liquid
culture and on overlay spot plates (Figures 6a and 6c). The genes
wzt and wzm encode the ATP-binding component and membrane
component of a CPA-dedicated ABC transporter. Therefore, these
mutants lack the CPA on their cell surface, but still produce the
O-specific antigen. The activity of pyocin SD2 against these two
mutant strains was reduced when compared with wild type PAO1
suggesting that CPA-binding is involved in pyocin SD2 activity.
To determine if pyocin SD2 is able to directly bind the CPA
we utilized ITC. ITC binding isotherms for titration of pyocin
SD2 into LPS-derived carbohydrates (a mixture of CPA and the
O-specific antigen containing polysaccharides) from wild-type
PAO1 gave strong saturable exothermic heats of binding with an
average Kd = 0.58 (+−0.36) μM (Figure 7a, Table 2). Conversely,
no saturable binding isotherm was obtained when pyocin SD2
was titrated into an equivalent concentration of LPS carbohydrate
from PAO1wzt (Figure 7b). These data confirm a direct interaction
between pyocin SD2 and the CPA of P. aeruginosa LPS. Overlay
spot plate assays with PAO1wzt and high concentrations of pyocin
SD2 (300 μM) did not produce central zones of bacterial growth
or ‘halos’ within the clear zone of killing, showing a lack of FpvAI
saturation in the absence of CPA-binding.
As pyocins SD2 and S2 differ only in their cytotoxic domains
the above experiment was repeated with pyocin S2 to determine
if the CPA-binding determinant of pyocin SD2 is located within
this domain. Titration of pyocin S2 into LPS carbohydrates from
PAO1 and PAO1wzt indicated that the affinity of pyocin S2 for
CPA (average Kd = 0.38 (+−0.24) μM) is comparable to that of
Figure 6 Pyocin SD2 requires the CPA for efficient killing
(a) Inhibition of growth of P. aeruginosa PAO1 and P. aeruginosa PAO1wzt by pyocin SD2 (1–5:
313 μg · ml− 1, 2-fold dilutions) as shown by a soft agar overlay spot-test. Ten microlitres of
purified pyocin SD2 was spotted on to a growing lawn of cells. Clear zones indicate cell death.
(b) Representative growth curves for P. aeruginosa strains PAO1 and PAO1wzt grown in LB
broth for 180 min with and without the addition of 3 μM pyocin SD2. OD600 measured 0, 30,
60, 90 and 180 min after pyocin treatment. Error bars represent the standard error mean between
replicate samples (n = 3). PAO1 (circle), PAO1wzt (up triangle), PAO1 + pyocin SD2 (square)
and PAO1wzt + pyocin SD2 (down triangle). (c) Percent killing for one of the replicates in (b).
Ten microlitres of cells (10-fold serial dilutions) were spotted on LB agar plates at 60, 90 and
180 min after pyocin SD2 treatment, incubated at 37◦C for 16 h and CFU determined. % killing
determined by comparison to untreated controls.
pyocin SD2 (Figures 7c and 7d, Table 2). These data show that the
CPA-binding motif is located within the N-terminal 558 residues.
To further dissect the CPA-binding region, three pyocin S2/SD2
truncation constructs were created (Figure 8a). Pyocin S2318,
with the first 318 residues (unstructured region and helical region)
removed, did not bind to LPS carbohydrates from PAO1, as
determined by ITC (Figure 8b, Table 2). This protein variant
was purified via a His6-tag on the pyocin S2 immunity protein
demonstrating protein folding. Far-UV CD also showed this
protein to have helical content (characteristic α-helix peaks near
208 nm and 222 nm) (Figure 8g). These data suggest that the CPA-
binding motif is located in the first 318 amino acids of pyocins
S2/SD2 and not in the CCPD. Pyocin S2(1–209), which consists
of the first 209 amino acids only, showed no binding to LPS
carbohydrates from PAO1 (Figure 8c). This fragment did retain
the ability to bind to the surface of P. aeruginosa PAO1 however
(Figures 1c and 2d) and far-UV CD analysis showed it to be
helical, due to the characteristic α-helix peaks near 208 nm and
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Figure 7 Pyocins SD2 and S2 bind to the CPA of P. aeruginosa LPS
(a) ITC binding isotherm of pyocin SD2 (150 μM) titrated into isolated LPS-derived polysaccharide (3 mg ml− 1) from wild-type P. aeruginosa PAO1. Saturable heats were observed indicative of
an interaction. Data were fitted to a single-binding site model that yielded a K d = 0.22 +− 0.02 μM. Reactions were performed in 0.2 M sodium phosphate buffer, pH 7.5 at 30◦C using a MicroCal
iTC200. (b) ITC isotherm of pyocin SD2* (111 μM) titrated into isolated LPS-derived polysaccharide (1 mg · ml− 1) from PAO1wzt . No saturable binding isotherm was observed. (c) ITC binding
isotherm of pyocin S2 (150 μM) titrated into isolated LPS-derived polysaccharide (3 mg · ml− 1) from wild-type P. aeruginosa PAO1. Data were fitted to a single-binding site model that yielded
a K d = 0.62 +− 0.04 μM. Reactions were performed in 0.2 M sodium phosphate buffer, pH 7.5 at 30◦C using a MicroCal iTC200. (d) ITC isotherm of pyocin S2* (111 μM) titrated into isolated
LPS-derived polysaccharide (1 mg · ml− 1) from PAO1wzt . No saturable binding isotherm was observed. Errors reported are the error for the single site binding model fit. *Reactions were performed
in 0.2 M sodium phosphate buffer, pH 7.5 at 25◦C using a MicroCal VP-ITC.
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Table 2 ITC binding parameters for pyocins titrated into LPS sugars from P. aeruginosa PAO1
*Errors in parentheses refer to errors from fit of data from individual experiments to a single-binding site model. †Mean of the two independent experiments (+−S.E.M.). ‡N fixed to 0.10 for fitting
(see Materials and methods). ND – not determined.
Pyocin [Protein] (μM) [LPS sugars] (mg · ml− 1) H (+−)* (kcal · mol− 1) N (+−)* (sites) S (cal · mol− 1 · deg− 1) K d (+−)* (μM) Average K d (+−)† (μM)
SD2 300 3.0 − 25.0 (2.4) 0.11 (0.01) −55 0.93 (0.09) 0.58 (0.36)
SD2 150 3.0 − 17.4 (0.7) 0.11 (0.00) −28 0.22 (0.02)
S2 75 3.0 − 16.6 (0.6) 0.12 (0.00) −24 0.14 (0.03) 0.38 (0.24)
S2 150 3.0 − 18.3 (0.9) 0.11 (0.00) −33 0.62 (0.04)
S5 300 3.0 − 28.5 (3.9) 0.13 (0.01) −68 1.94 (0.19) 1.19 (0.75)
S5 150 3.0 − 17.9 (0.6) 0.14 (0.00) −31 0.44 (0.01)
AP41 100 1.0 ND – − – –
AP41 150 3.0 ND – − –
SD1 300 3.0 ND – − – –
SD1 300 3.0 ND – − –
SD3 257 3.0 − 23.4 (2.8) 0.10 (0.01) −51 1.84 (0.17) 1.47 (0.37)
SD3 150 3.0 − 16.3 (0.9) 0.12 (0.00) −27 1.10 (0.04)
S2318 257 3.0 ND – − – –
S2318 150 3.0 ND – − –
S2(209) 300 3.0 ND – − – –
S2(209) 175 1.0 ND – − –
SD2216 300 3.0 − 47.0 (4.0) 0.10‡ −134 21.32 (0.55) 22.31 (0.99)
SD2216 300 3.0 − 67.8 (5.8) 0.10‡ −203 23.29 (0.59)
222 nm (Figure 8g). This result suggests that amino acids 210–318
are involved in pyocin S2/SD2 CPA-binding. The final construct,
pyocin SD2216, weakly interacted with PAO1 LPS-derived
carbohydrates (average Kd = 22.3 (+− 0.99) μM) (Figures 8d and
8e, Table 2). Importantly, this interaction was shown to be specific
for CPA as no heats of binding were detected between SD2216
and LPS carbohydrates from PAO1wzt (Figure 8f). This protein
variant was purified via a His6-tag on the pyocin SD2 immunity
protein demonstrating protein folding. Far-UV CD analysis of
SD2216 gave a secondary structure profile similar to full length
pyocin SD2 indicating that the protein is folded (Figure 8h). This
mechanism of cell targeting was first reported for pyocin L1,
a lectin-like bacteriocin with the conserved sugar-binding motif
QxDxNxVxY where x is any amino acid [21]. Although the S-
type pyocins do not possess a homologous sugar-binding motif,
we show that the major CPA-binding determinant lies within the
helical region between amino acids 217–318 of pyocins S2/SD2.
However, other regions in the protein may also contribute to the
binding of this large substrate or alternatively the binding affinity
may have been affected by changes in protein stability caused by
the truncation site in the middle of the helical region. These data
show that the helical region of pyocins S2/SD2 is involved in both
CPA-binding and FpvAI binding.
CPA-binding by pyocins is a common mechanism of cell targeting
Interestingly, amino acids 210–318 of pyocins S2/SD2 share
76% sequence homology to amino acids of 208–300 of pyocin
S5. Outside these regions pyocin S5 shares <30% sequence
homology with pyocins S2/SD2. As these amino acids house
the major CPA-binding determinant of pyocins S2/SD2, the
observed homology predicts that pyocin S5 also binds to the CPA.
CPA-binding by pyocin S5 was confirmed by ITC using PAO1
LPS-derived carbohydrates [average Kd = 1.19 (+− 0.75) μM](Figures 9a and 9b, Table 2). In addition, sequence alignments
showed that pyocins S3/SD3 (amino acids 55–150) share 44%
sequence identity with amino acids 210–318 of pyocins S2/SD2
and in contrast pyocins S1/SD1 and AP41 share no significant
sequence homology with this region of pyocins S2/SD2. Based
on these analyses it was predicted that pyocins S3/SD3 would
bind to the CPA and pyocins S1/SD1 and AP41 would not. Pyocin
SD3 was shown to bind LPS carbohydrates from PAO1 with an
average Kd = 1.47 (+− 0.37) μM and pyocins SD1 and AP41
showed no CPA-binding (Figures 9c–9f, Table 2). This study
shows that the strategy of utilizing both the CPA and a protein
receptor for cell targeting is common among pyocins. As the
majority of P. aeruginosa strains produce the CPA [47], targeting
of this cell surface motif is an excellent means of concentrating
pyocins at the cell surface where they can then search for their
receptors/translocators; a mechanism that serves to increase the
efficiency of pyocin killing (Figure 6). Importantly in terms
of therapeutic applications, CPA is the major surface antigen
of P. aeruginosa in the cystic fibrosis lung [47–50] and could
represent a potential strategy for targeting of anti-pseudomonal
therapeutics.
Pyocin SD2 can afford protection against a lethal P. aeruginosa
infection in vivo
The potency, active uptake and species-specificity of pyocins
make them ideal therapeutic candidates for the treatment of P.
aeruginosa infections. To assess the potential of pyocin SD2 in
the treatment of P. aeruginosa lung infection in vivo, we utilized a
murine model. To determine if pyocin SD2 can afford protection
against a lethal P. aeruginosa infection, mice (n = 6) were infected
intranasally with P. aeruginosa PAO1 and treated intranasally 1 h
post-infection with pyocin SD2 (25 μl at 3 mg ml− 1). A second
group of mice were treated with pyocin S2 (25 μl at 3 mg · ml− 1)
1 h post-infection. Pyocin S2-treated mice were included as a
control as P. aeruginosa PAO1 is a pyocin S2 producer and is
therefore resistant to pyocin S2. PBS-treated control mice and
pyocin S2-treated mice were culled 6 h post-infection due to the
severity of the illness and high levels of bacteria (approximately
105 CFU/lung) were recovered from these mice. Pyocin SD2
treated mice showed no signs of illness and survived to the end-
point of the experiment (24 h post-infection). Very low bacterial
counts were recovered from the lungs of these mice (5 CFU/lung)
and the recovered colonies showed no resistance to pyocin SD2.
The efficacy of pyocin SD2 as demonstrated by its ability to afford
c© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution Licence 4.0 (CC BY).
Mechanistic details of pyocin SD2 activity 2355
Figure 8 The helical domain of pyocins S2/SD2 is involved in CPA-binding
(a) Schematic of the protein variants used in this study. (b) ITC binding isotherm of pyocin S2318 (150 μM) titrated into isolated LPS-derived polysaccharide (3 mg · ml− 1) from wild-type P.
aeruginosa PAO1. No saturable binding isotherm was observed. (c) ITC binding isotherm of pyocin S2 (1–209) (300 μM) titrated into isolated LPS-derived polysaccharide (3 mg · ml− 1) from
wild-type P. aeruginosa PAO1. No saturable binding isotherm was observed. (d) ITC binding isotherm of pyocin SD2216 (888 μM) titrated into isolated LPS-derived polysaccharide (1.5 mg · ml− 1)
from wild-type P. aeruginosa PAO1. Saturable heats were observed indicative of a weak interaction. (e) ITC binding isotherm of pyocin SD2216 (300 μM) titrated into isolated LPS-derived
polysaccharide (3 mg · ml− 1) from wild-type P. aeruginosa PAO1. Heats were observed indicative of a weak interaction. Data were fitted to a single-binding site model, with N set to 0.1, that yielded a
K d = 23.3 +− 0.59 μM. (f) ITC isotherm of pyocin SD2216 (300 μM) titrated into isolated LPS-derived polysaccharide (3 mg · ml− 1) from PAO1wzt . No saturable binding isotherm was observed.
Reactions were performed in 0.2 M sodium phosphate buffer, pH 7.5 at 30◦C using a MicroCal iTC200. Errors reported are the error of the single site binding model fit. (g) Far-UV circular CD spectra
were scanned from 250 to 195 nm three times at 25◦C for pyocin S2 (green line), pyocin S2(1–209) (blue line) and pyocin S2318 (purple line). All proteins have helical content demonstrating
folding. (h) CD spectra for pyocin SD2 (orange line) and truncated pyocin SD2216 (light blue line). Both proteins have helical content demonstrating folding. Proteins in 0.2 M sodium phosphate
buffer, pH 7.5 at 25◦C were diluted to a concentration of 15–150 μg · ml− 1 and CD spectra were recorded on a J-815 spectropolarimeter (Jasco) in a 0.1 cm quartz cuvette. The final spectra were
represented by molar ellipticity, ε (mdeg · M-1 · cm-1).
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Figure 9 CPA-binding ability of pyocins SD1, SD3, S5 and AP41
(a) ITC binding isotherm of pyocin S5 (150 μM) titrated into isolated LPS-derived polysaccharide (3 mg · ml− 1) from wild-type P. aeruginosa PAO1. Strong, saturable heats were observed indicative
of a strong interaction. Data were fitted to a single-binding site model that yielded a K d = 0.44 +− 0.01 μM. (b) ITC isotherm of pyocin S5 (150 μM) titrated into isolated LPS-derived polysaccharide
(3 mg · ml− 1) from PAO1wzt . No saturable binding isotherm was observed. (c) ITC isotherm of pyocin SD1 (300 μM) titrated into isolated LPS-derived polysaccharide (3 mg · ml− 1) from PAO1.
No saturable binding isotherm was observed. (d) ITC binding isotherm of pyocin SD3 (150 μM) titrated into isolated LPS-derived polysaccharide (3 mg · ml− 1) from wild-type P. aeruginosa PAO1.
Saturable heats were observed indicative of an interaction. Data were fitted to a single-binding site model that yielded a K d = 1.1 +− 0.04 μM. (e) ITC isotherm of pyocin SD3 (150 μM) titrated into
isolated LPS-derived polysaccharide (3 mg · ml− 1) from PAO1wzt. No saturable binding isotherm was observed. (f) ITC binding isotherm of pyocin AP41* (150 μM) titrated into isolated LPS-derived
polysaccharide (3 mg ml− 1) from wild-type P. aeruginosa PAO1. No saturable binding isotherm was observed. Errors reported are the error of the single site binding model fit. *Reactions were
performed in 0.2 M sodium phosphate buffer, pH 7.5 at 25◦C using a MicroCal VP-ITC.
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Figure 10 Pyocin binding and translocation model
(a) Newly proposed domain architecture of pyocin SD2. (b) Proposed model of pyocin binding
and translocation. Pyocin SD2 binds to the CPA on the cell surface of P. aeruginosa, via the
receptor and CPA-binding domain, which orientates the N-terminus close to the TonB-dependent
outer membrane protein FpvAI. The intrinsically unstructured translocation domain is then
positioned to thread through the FpvAI pore and interact with translocation machinery. The
interaction of TonB with FpvAI is important for pyocin SD2 translocation across the outer
membrane.
protection against a lethal P. aeruginosa infection, demonstrates
the potential of pyocins as potent narrow spectrum therapeutics.
CONCLUSION
Understanding the mechanisms by which biomolecules cross the
P. aeruginosa outer membrane has the potential to inspire the
development of new antibiotics. In this work we propose a model
for the cell targeting and translocation of pyocins S2/SD2 across
the P. aeruginosa outer membrane. In this model, pyocins S2/SD2
are concentrated at the cell surface, via binding to the CPA, from
here they can efficiently locate FpvAI in the outer membrane.
The requirement for an intact TonB binding box in the FpvAI
receptor for pyocin killing indicates that the receptor also plays a
role in pyocin translocation although the exact nature of this role
and subsequent steps in the translocation process remain poorly
understood (Figure 10). Additionally, we show that pyocins are
promising therapeutics in their own right. The ability of pyocin
SD2 to treat a lethal P. aeruginosa lung infection in a murine
model shows that pyocin SD2 has excellent antimicrobial activity
in vivo. The identification of pyocins such as pyocins SD1, SD2
and SD3 also serves to broaden the number of potential pyocin
candidates for therapeutic development. In an era where pan-
drug resistant P. aeruginosa isolates are being more frequently
isolated, the development of novel therapeutic approaches to treat
P. aeruginosa infection, such as those presented in this study, are
essential.
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